New antibody VIS649 tested in humans for first time to fight kidney disease

NCT ID NCT03719443

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety of a new drug called VIS649 in 51 healthy volunteers. VIS649 is an antibody that blocks a protein called APRIL, which is thought to play a role in IgA nephropathy, a kidney disease. The study gave single doses of the drug or a placebo and monitored for side effects. Results will help decide if further testing in patients is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VIS649 (an antibody that blocks a protein called APRIL)
What this could lead to: If safe and effective, VIS649 could become a new treatment option for IgA nephropathy, a kidney disease that currently has limited therapies.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug actually works for the disease. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY IGAN - IGA NEPHROPATHY IMMUNOGLOBULIN A NEPHROPATHY

Contacts and locations

Locations

California Clinical Trials Medical Group

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.